We are live on ! Find out more

Arcus Biosciences

RCUS

Market cap $3.12B

24.47 USD

+0.64

2.69%

At close Updated Oct 9, 2:23 PM EDT

1 day

2.69%

5 days

1.16%

1 month

-14.11%

3 months

-18.32%

6 months

5.11%

Year to date

5.07%

1 year

61.41%

5 years

-23.2%

10 years

43.94%

About: Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Employees: 601

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 19%

Neutral 76.2%

Negative 4.8%

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company's common stock at an exercise price per share of $26.39, which was the closing.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City. The event will highlight new data from the ARC-20 platform study, which is evaluating casdatif.

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company's common stock at an exercise price per share of $29.06, which was the.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2026 Biotech Back to School Conference Date: Wednesday, September 9th, 2026 Location: New York, NY Format: Fireside chat &amp.

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $28.72, which was the.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™